IMIB- Irraxca, one of the scientific partners of ULISES, participated in this congress presenting the poster communication "Assessment of the efficacy of a monoclonal antibody against pancreatic tumour cells by complement-dependent cytotoxicity assay".
Last September, ULISES’s partner IMIB- Irraxca attended the European Congress of Immunology hosted by the European Federation of Immunological Societies and the Irish Society for Immunology.
At the event, our partner presented a poster communication entitled “Assessment of the efficacy of a monoclonal antibody against pancreatic tumour cells by complement-dependent cytotoxicity assay”.
This work investigated the efficacy of the specific monoclonal antibody (mAb) by complement-dependent cytotoxicity assay against pancreatic ductal carcinoma cells (PANC-1) and PANC-1 cells transfected to express the target molecule. The results showed a significant reduction in cell viability after treatment with the mAb in the case of the transfected lines, indicating its potential as a therapeutic agent for targeted therapy. These results demonstrate the efficacy of ULISES therapy in vitro.
The poster communication is available at this link.
(Photo Credits: IMIB-Irraxca)
